LOGIN  |  REGISTER
Astria Therapeutics
Astria Therapeutics

Sonida Senior Living Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call

March 03, 2025 | Last Trade: US$21.76 0.18 0.83

DALLAS / Mar 03, 2025 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or the “Company”) (NYSE: SNDA), a leading owner, operator and investor in communities and services for seniors, today announced that it will issue its fourth quarter and full year 2024 earnings results before the market opens for trading on Monday, March 17, 2025. The Company will then host a conference call and webcast to review its financial performance and operating results at 11:00 a.m. Eastern Time.

The dial-in number for the conference call is (800) 715-9871 (or +1 (646) 307-1963 for international callers), and the participant passcode is 4619110. A live webcast can be accessed here. All participants are asked to register and connect 10 minutes prior to the start of the call/webcast to ensure connectivity.

A webcast replay will be available on the Sonida IR website and accessible for replay for 12 months. A telephonic replay will be available for 7 days at (800) 770-2030, passcode 4619110.

About Sonida

Dallas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate, resident-centric services and care as well as engaging programming operating 94 senior housing communities in 20 states with an aggregate capacity of over 10,000 residents, including 81 communities which the Company owns (including eight communities in which the Company owns varying interests through two separate joint ventures), and 13 communities that the Company manages on behalf of a third-party.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, X or LinkedIn. 

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page